Determinants of androgen deprivation therapy use for prostate cancer: Role of the urologist

Vahakn B. Shahinian, Yong Fang Kuo, Jean L. Freeman, James Goodwin

Research output: Contribution to journalArticle

92 Citations (Scopus)

Abstract

Background: The use of androgen deprivation therapy for prostate cancer has been increasing, even in settings for which there is weak or no evidence of efficacy. This pattern suggests that factors other than the typical patient and tumor characteristics may be driving its use. We assessed the importance of the physician as a determinant of the use of androgen deprivation therapy in prostate cancer in a population-based, retrospective cohort study using the Surveillance, Epidemiology and End-Results-Medicare linked database. Methods: Participants included 61717 men with incident prostate cancer diagnosed from January 1, 1992, through December 31, 1999, and 1802 urologists providing care to them within 1 year of cancer diagnosis. Multilevel analyses were used to estimate and partition the variance in use of androgen deprivation therapy within 6 months of diagnosis between patient or tumor characteristics and urologist to examine the relative contribution of each component to androgen deprivation therapy. Results: The percentage of the total variance in the use of androgen deprivation therapy attributable to the urologist was consistently higher than that attributable to tumor or patient characteristics. This pattern was most pronounced for patients diagnosed from January 1, 1997, through December 31, 1999, in which 22.56% of the total variance in use of androgen deprivation therapy was attributable to the urologist, 9.71% to tumor characteristics (stage or grade), and 4.29% to patient characteristics (age, ethnicity, socio-economic status, comorbidity, geographic region, or year of diagnosis). Conclusions: Which urologist a patient sees may be more important in determining whether they will receive androgen deprivation therapy than tumor or patient characteristics.

Original languageEnglish (US)
Pages (from-to)839-845
Number of pages7
JournalJournal of the National Cancer Institute
Volume98
Issue number12
DOIs
StatePublished - Jun 21 2006

Fingerprint

Androgens
Prostatic Neoplasms
Neoplasms
Therapeutics
Multilevel Analysis
Medicare
Urologists
Comorbidity
Epidemiology
Cohort Studies
Retrospective Studies
Economics
Databases
Physicians
Population

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Determinants of androgen deprivation therapy use for prostate cancer : Role of the urologist. / Shahinian, Vahakn B.; Kuo, Yong Fang; Freeman, Jean L.; Goodwin, James.

In: Journal of the National Cancer Institute, Vol. 98, No. 12, 21.06.2006, p. 839-845.

Research output: Contribution to journalArticle

@article{7c3c39a5ff714a7282a61e36f1fc5d83,
title = "Determinants of androgen deprivation therapy use for prostate cancer: Role of the urologist",
abstract = "Background: The use of androgen deprivation therapy for prostate cancer has been increasing, even in settings for which there is weak or no evidence of efficacy. This pattern suggests that factors other than the typical patient and tumor characteristics may be driving its use. We assessed the importance of the physician as a determinant of the use of androgen deprivation therapy in prostate cancer in a population-based, retrospective cohort study using the Surveillance, Epidemiology and End-Results-Medicare linked database. Methods: Participants included 61717 men with incident prostate cancer diagnosed from January 1, 1992, through December 31, 1999, and 1802 urologists providing care to them within 1 year of cancer diagnosis. Multilevel analyses were used to estimate and partition the variance in use of androgen deprivation therapy within 6 months of diagnosis between patient or tumor characteristics and urologist to examine the relative contribution of each component to androgen deprivation therapy. Results: The percentage of the total variance in the use of androgen deprivation therapy attributable to the urologist was consistently higher than that attributable to tumor or patient characteristics. This pattern was most pronounced for patients diagnosed from January 1, 1997, through December 31, 1999, in which 22.56{\%} of the total variance in use of androgen deprivation therapy was attributable to the urologist, 9.71{\%} to tumor characteristics (stage or grade), and 4.29{\%} to patient characteristics (age, ethnicity, socio-economic status, comorbidity, geographic region, or year of diagnosis). Conclusions: Which urologist a patient sees may be more important in determining whether they will receive androgen deprivation therapy than tumor or patient characteristics.",
author = "Shahinian, {Vahakn B.} and Kuo, {Yong Fang} and Freeman, {Jean L.} and James Goodwin",
year = "2006",
month = "6",
day = "21",
doi = "10.1093/jnci/djj230",
language = "English (US)",
volume = "98",
pages = "839--845",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - Determinants of androgen deprivation therapy use for prostate cancer

T2 - Role of the urologist

AU - Shahinian, Vahakn B.

AU - Kuo, Yong Fang

AU - Freeman, Jean L.

AU - Goodwin, James

PY - 2006/6/21

Y1 - 2006/6/21

N2 - Background: The use of androgen deprivation therapy for prostate cancer has been increasing, even in settings for which there is weak or no evidence of efficacy. This pattern suggests that factors other than the typical patient and tumor characteristics may be driving its use. We assessed the importance of the physician as a determinant of the use of androgen deprivation therapy in prostate cancer in a population-based, retrospective cohort study using the Surveillance, Epidemiology and End-Results-Medicare linked database. Methods: Participants included 61717 men with incident prostate cancer diagnosed from January 1, 1992, through December 31, 1999, and 1802 urologists providing care to them within 1 year of cancer diagnosis. Multilevel analyses were used to estimate and partition the variance in use of androgen deprivation therapy within 6 months of diagnosis between patient or tumor characteristics and urologist to examine the relative contribution of each component to androgen deprivation therapy. Results: The percentage of the total variance in the use of androgen deprivation therapy attributable to the urologist was consistently higher than that attributable to tumor or patient characteristics. This pattern was most pronounced for patients diagnosed from January 1, 1997, through December 31, 1999, in which 22.56% of the total variance in use of androgen deprivation therapy was attributable to the urologist, 9.71% to tumor characteristics (stage or grade), and 4.29% to patient characteristics (age, ethnicity, socio-economic status, comorbidity, geographic region, or year of diagnosis). Conclusions: Which urologist a patient sees may be more important in determining whether they will receive androgen deprivation therapy than tumor or patient characteristics.

AB - Background: The use of androgen deprivation therapy for prostate cancer has been increasing, even in settings for which there is weak or no evidence of efficacy. This pattern suggests that factors other than the typical patient and tumor characteristics may be driving its use. We assessed the importance of the physician as a determinant of the use of androgen deprivation therapy in prostate cancer in a population-based, retrospective cohort study using the Surveillance, Epidemiology and End-Results-Medicare linked database. Methods: Participants included 61717 men with incident prostate cancer diagnosed from January 1, 1992, through December 31, 1999, and 1802 urologists providing care to them within 1 year of cancer diagnosis. Multilevel analyses were used to estimate and partition the variance in use of androgen deprivation therapy within 6 months of diagnosis between patient or tumor characteristics and urologist to examine the relative contribution of each component to androgen deprivation therapy. Results: The percentage of the total variance in the use of androgen deprivation therapy attributable to the urologist was consistently higher than that attributable to tumor or patient characteristics. This pattern was most pronounced for patients diagnosed from January 1, 1997, through December 31, 1999, in which 22.56% of the total variance in use of androgen deprivation therapy was attributable to the urologist, 9.71% to tumor characteristics (stage or grade), and 4.29% to patient characteristics (age, ethnicity, socio-economic status, comorbidity, geographic region, or year of diagnosis). Conclusions: Which urologist a patient sees may be more important in determining whether they will receive androgen deprivation therapy than tumor or patient characteristics.

UR - http://www.scopus.com/inward/record.url?scp=33745258787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745258787&partnerID=8YFLogxK

U2 - 10.1093/jnci/djj230

DO - 10.1093/jnci/djj230

M3 - Article

C2 - 16788157

AN - SCOPUS:33745258787

VL - 98

SP - 839

EP - 845

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 12

ER -